



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Huesca *et al.*

Application No. 10/579,149

371(c) Date: January 19, 2007

For: ARYL IMIDAZOLES AND THEIR
USE AS ANTI-CANCER AGENTS

Art Unit: 1614

Examiner: Anderson, James D.

Confirmation: 8922

PETITION FOR CORRECTION OF INVENTORSHIP UNDER 37 C.F.R. § 1.48(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

BALLARD SPAHR LLP
Customer Number 23859

Sir:

In accordance with MPEP § 201.03 and 37 C.F.R. § 1.48(a), Applicants hereby request that the inventorship of the above-identified application be amended to correctly identify the inventors as Mario Huesca, Raed Al-Qawasmeh, Aiping H. Young, Yoon Lee, **and Lisa Lock**. The above-identified application entered the US National Phase on May 12, 2006. On January 16, 2007, a Declaration was filed that identified Mario Huesca, Raed Al-Qawasmeh, Aiping H. Young, and Yoon Lee as inventors. It came to the attention of the undersigned attorney that Lisa Lock was inadvertently omitted as an inventor. Appropriate correction is requested.

In addition to this request to correct the inventorship, this petition is accompanied by:

- (1) a statement from Lisa Lock, who is being added as an inventor, indicating that the inventorship error occurred without deceptive intent on her part;
- (2) a declaration executed by all of the actual inventors;
- (3) the \$130 fee set forth in 37 CFR § 1.17(i); and
- (4) the written consent of the Assignee, Lorus Therapeutics, Inc.

09/28/2009 RHEBRAHT 00000044 10579149


01 FC:1464

130.00 OP


ATTORNEY DOCKET NO. 13198.0007U1
APPLICATION NO. 10/579,149

A Credit Card Payment Form PTO-2038 authorizing payment in the amount of \$130.00, the processing fee set forth in 37 CFR § 1.17(i), is also enclosed. This amount is believed to be correct; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,
BALLARD SPAHR LLP


Christopher L. Curfman, JD, PhD
Registration No. 52,787

BALLARD SPAHR LLP
Customer Number 23859
(678) 420-9300 (phone)
(678) 420-9301 (fax)

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. § 1.8			
I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop AMENDMENT , Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.			
Name of Person Mailing (Print/Type)	Christopher L. Curfman		
Signature		Date	September 23, 2009



ATTORNEY DOCKET NO. 13198.0007U1
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Huesca *et al.*

Application No. 10/579,149

371(c) Date: January 19, 2007

For: ARYL IMIDAZOLES AND THEIR
USE AS ANTI-CANCER AGENTS

)
)
) Art Unit: 1614
)
)

) Examiner: Anderson, James D.
)

) Confirmation: 8922
)
)

STATEMENT ACCOMPANYING PETITION FOR CORRECTION OF
INVENTORSHIP UNDER 37 C.F.R. § 1.48(a)(2)

Sir:

I, Lisa Lock, state that I am a co-inventor of the subject matter claimed in the above-referenced application and that the inventorship error in failing to name me as an inventor of the above-referenced application occurred without any deceptive intention on my part.

Lisa Lock
Lisa Lock

October 22, 2007
Date